Trial Profile

Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Carboplatin; Cisplatin; Fluorouracil
Indications Adenocarcinoma; Head and neck cancer; Paranasal-sinus-neoplasms; Sinonasal-undifferentiated-carcinoma; Squamous cell cancer
Focus Therapeutic Use

16 May 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
16 May 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2025.
18 Sep 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com